CUPISCO study: Molecularly guided therapy versus standard chemotherapy in patients with carcinoma of unknown primary

被引：0
|
作者：
Britschgi, Christian [1 ]
Kraemer, Alwin [2 ,3 ]
Losa, Ferran [4 ]
Gay, Laurie M. [5 ]
Page, Damian R. [6 ]
Foser, Stefan [6 ]
Mughal, Tariq I. [7 ]
Ross, Jeffrey S. [5 ]
Baciarello, Giulia [8 ]
Mileshkin, Linda R. [9 ]
Osborne, Stuart [6 ]
Moch, Holger [1 ]
机构：
[1] Univ Hosp Zurich, Zurich, Switzerland
[2] Heidelberg Univ, German Canc Res Ctr DKFZ, Heidelberg, Germany
[3] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany
[4] Hosp St Joan Despi Moises Broggi, Med Oncol Dept, Barcelona, Spain
[5] Fdn Med Inc, Cambridge, MA USA
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Tufts Univ, Med Ctr, Hematol & Oncol, Boston, MA 02111 USA
[8] Gustave Roussy, Dept Med Oncol, Villejuif, France
[9] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
来源：
SWISS MEDICAL WEEKLY | 2019年 / 149卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1063
引用
收藏
页码：13S / 13S
页数：1
相关论文
共 50 条
  • [1] Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
    Kraemer, Alwin
    Bochtler, Tilmann
    Pauli, Chantal
    Shiu, Kai-Keen
    Cook, Natalie
    de Menezes, Juliana Janoski
    Pazo-Cid, Roberto A.
    Losa, Ferran
    Robbrecht, Debbie G. J.
    Tomasek, Jiri
    Arslan, Cagatay
    Ozguroglu, Mustafa
    Stahl, Michael
    Bigot, Frederic
    Kim, Sun Young
    Naito, Yoichi
    Italiano, Antoine
    Chalabi, Nassera
    Duran-Pacheco, Gonzalo
    Michaud, Chantal
    Scarato, Jeremy
    Thomas, Marlene
    Ross, Jeffrey S.
    Moch, Holger
    Mileshkin, Linda
    LANCET, 2024, 404 (10452): : 527 - 539
  • [2] Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy
    Kraemer, A.
    Losa, F.
    Gay, L. M.
    Page, D. R.
    Foser, S.
    Mughal, T. I.
    Ross, J. S.
    Baciarello, G.
    Mileshkin, L. R.
    Osborne, S.
    Moch, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study
    Westphalen, C. B.
    Federer-Gsponer, J.
    Pauli, C.
    Karapetyan, A. R.
    Chalabi, N.
    Duran-Pacheco, G.
    Beringer, A.
    Bochtler, T.
    Cook, N.
    Hoglander, E.
    Jin, D. X.
    Losa, F.
    Mileshkin, L.
    Moch, H.
    Ross, J. S.
    Sokol, E. S.
    Tothill, R. W.
    Kramer, A.
    ESMO OPEN, 2023, 8 (06)
  • [4] Molecularly guided therapy improves survival outcomes for patients with a cancer of unknown primary
    Nierengarten, Mary Beth
    CANCER, 2024, 130 (24)
  • [5] Baseline mutational profiles of patients with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
    Mileshkin, Linda
    Karapetyan, Armen R.
    Beringer, Andreas
    Bochtler, Tilmann
    Chalabi, Nassera
    Cook, Natalie
    Duran-Pacheco, Gonzalo
    Golding, Sophie
    Hoglander, Elen
    Losa, Ferran
    Moch, Holger
    Pauli, Chantal
    Ross, Jeff S.
    Sokol, Ethan S.
    Tothill, Richard W.
    Westphalen, C. Benedikt
    Kraemer, Alwin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 129 - 130
  • [6] Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
    Westphalen, C. B.
    Karapetyan, A.
    Beringer, A.
    Bochtler, T.
    Chalabi, N.
    Cook, N.
    Duran-Pacheco, G.
    Golding, S.
    Hoeglander, E.
    Losa, F.
    Mileshkin, L.
    Moch, H.
    Pauli, C.
    Ross, J.
    Sokol, E.
    Tothill, R.
    Kraemer, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1227 - S1228
  • [7] EMPIRIC CHEMOTHERAPY IN PATIENTS WITH CARCINOMA OF UNKNOWN PRIMARY SITE
    SPORN, JR
    GREENBERG, BR
    AMERICAN JOURNAL OF MEDICINE, 1990, 88 (01): : 49 - 55
  • [8] Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
    Westphalen, Benedikt
    Karapetyan, Armen R.
    Beringer, Andreas
    Bochtler, Tilmann
    Chalabi, Nassera
    Cook, Natalie
    Duran-Pacheco, Gonzalo
    Golding, Sophie
    Hoglander, Elen
    Losa, Ferran
    Mileshkin, Linda
    Moch, Holger
    Pauli, Chantal
    Ross, Jeffrey S.
    Sokol, Ethan S.
    Tothill, Richard W.
    Kraemer, Alwin
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 40 - 40
  • [9] A challenging task - Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
    Pauli, C.
    Bochtler, T.
    Mileshkin, L.
    Baciarello, G.
    Losa, F.
    Ross, J.
    Pentheroudakis, G.
    Zarkavelis, G.
    Yalcin, S.
    Ozguroglu, M.
    Beringer, A.
    Foser, S.
    Scarato, J.
    Mueller-Ohldach, M.
    Moch, H.
    Kraemer, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
    Ross, Jeffrey S.
    Sokol, Ethan S.
    Moch, Holger
    Mileshkin, Linda
    Baciarello, Giulia
    Losa, Ferran
    Beringer, Andreas
    Thomas, Marlene
    Elvin, Julia A.
    Ngo, Nhu
    Jin, Dexter X.
    Kraemer, Alwin
    ONCOLOGIST, 2021, 26 (03): : E394 - E402
12345